2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

[1]  P. Merkel,et al.  LB004A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE , 2020 .

[2]  P. Jégo,et al.  Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. , 2019, Rheumatology.

[3]  U. Schönermarck,et al.  Kidney transplantation in ANCA-associated vasculitis , 2019, Journal of Nephrology.

[4]  D. Jayne,et al.  Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis , 2019, RMD Open.

[5]  N. Basu,et al.  Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study , 2019, BMC Nephrology.

[6]  V. Tesar,et al.  Avacopan in the treatment of ANCA-associated vasculitis , 2018, Expert opinion on investigational drugs.

[7]  P. Ravaud,et al.  Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2) , 2018, Annals of the rheumatic diseases.

[8]  S. Andrulli,et al.  Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial , 2017, PloS one.

[9]  G. Baron,et al.  Adding Azathioprine to Remission‐Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors , 2017, Arthritis & rheumatology.

[10]  M. Haubitz,et al.  Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis , 2017, Annals of the rheumatic diseases.

[11]  S. Yancey,et al.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[12]  W. Mccune,et al.  Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy , 2017, Current opinion in rheumatology.

[13]  G. Guyatt,et al.  A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. , 2016, Journal of clinical epidemiology.

[14]  G. Guyatt,et al.  A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. , 2016, Journal of clinical epidemiology.

[15]  X. Mariette,et al.  Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety‐Two Patients , 2015, Arthritis & Rheumatology.

[16]  J. Ninet,et al.  Long‐Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss) , 2015, Arthritis care & research.

[17]  P. Merkel,et al.  Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) , 2014, Annals of the rheumatic diseases.

[18]  D. Chauveau,et al.  Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. , 2015, Rheumatology.

[19]  V. Cottin,et al.  Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's) , 2015, Medicine.

[20]  C. Pusey,et al.  Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease. , 2015, Ophthalmology.

[21]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[22]  A. Chaudhry,et al.  Long-term outcome of airway stenosis in granulomatosis with polyangiitis (Wegener granulomatosis): an observational study. , 2014, JAMA otolaryngology-- head & neck surgery.

[23]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[24]  P. Höglund,et al.  Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. , 2013, Kidney international.

[25]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[26]  L. Mouthon,et al.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. , 2013, Arthritis and rheumatism.

[27]  Kenneth G. C. Smith,et al.  Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. , 2012, Arthritis and rheumatism.

[28]  V. Tesar,et al.  Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up , 2011, Annals of the rheumatic diseases.

[29]  P. Merkel,et al.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. , 2012, Rheumatology.

[30]  U. Specks,et al.  Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience , 2011, Transplantation.

[31]  L. Mouthon,et al.  The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.

[32]  F. Sachse,et al.  Nasal surgery in patients with systemic disorders , 2011, GMS current topics in otorhinolaryngology, head and neck surgery.

[33]  V. Tesar,et al.  Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. , 2010, JAMA.

[34]  D. Scott,et al.  Epidemiology of ANCA-associated vasculitis. , 2010, Rheumatic diseases clinics of North America.

[35]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[36]  P. Seo.  Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis , 2010 .

[37]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[38]  L. Mouthon,et al.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. , 2008, The New England journal of medicine.

[39]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[40]  J. Coste,et al.  The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case–crossover study , 2008, Thorax.

[41]  C. Kallenberg,et al.  Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors. , 2007, Rheumatology.

[42]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[43]  K. De Groot,et al.  Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. , 2007, Rheumatology.

[44]  M. Pillinger.  High Incidence of Venous Thrombotic Events Among Patients With Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyMerkel PA, for the Wegener's Granulomatosis Etanercept Trial Research Group (Boston Univ; et al) Ann Intern Med 142:620–626, 2005§ , 2006 .

[45]  C. Feighery,et al.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.

[46]  P. Merkel,et al.  Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study , 2005, Annals of Internal Medicine.

[47]  D. Scott,et al.  What is known about the epidemiology of the vasculitides? , 2005, Best practice & research. Clinical rheumatology.

[48]  S. Aymé,et al.  Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. , 2004, Arthritis and rheumatism.

[49]  D. Sherris,et al.  Long‐Term Follow‐up of Repair of External Nasal Deformities in Patients With Wegener's Granulomatosis , 2002, The Laryngoscope.

[50]  L. Guillevin,et al.  Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. , 2001, Arthritis and rheumatism.

[51]  P. Dellaripa,et al.  Pneumocystis carinii pneumonia prophylaxis in patients with rheumatic diseases undergoing immunosuppressive therapy: prealence and associated features. , 2000, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[52]  P. Padfield,et al.  Renal , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[53]  M. Heller,et al.  Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. , 1996, Arthritis and rheumatism.

[54]  O. Lortholary,et al.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.

[55]  E W WALTON,et al.  Giant-cell Granuloma of the Respiratory Tract (Wegener's Granulomatosis) , 1958, British medical journal.